Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG, Appendix G) Performance Status of less than
             or equal to 1

          -  Life expectancy of at least 3 months, in the opinion of the investigator.

          -  Must have pathologically documented, and definitively diagnosed World Health
             Organization (WHO) grade 4, glioblastoma or lower grade malignant gliomas with
             EGFRvIII positive tumor

          -  Must have recurrent disease confirmed by MRI (Group 1) or completed SoC therapy such
             as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide
             according to local standards for newly diagnosed disease (Group 2)

          -  Hematological function as follows:

               -  Absolute neutrophil count (ANC) greater than 1500/mm3 (1.5 × 10 9/L)

               -  Platelet count greater than 100,000 mm3 (100 × 10 9/L)

               -  White blood cell (WBC) count greater than 3 × 10 9/L

               -  Hemoglobin greater than 9.0 g/dL

          -  Renal function as follows: serum creatinine less than 2.0 mg/dL and estimated
             glomerular filtration rate greater than or equal to 60 mL/min/1.73 m2 by MDRD and
             urine protein quantitative value of less than 30 mg/dL in urinalysis or less than or
             equal to 1+ on dipstick

          -  Hepatic function as follows:

               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) less than or
                  equal to 3.0 x upper limit of normal (ULN)

               -  Bilirubin less than or equal to 1.5 x ULN (unless considered due to Gilbert's
                  syndrome or hemolysis)

        Exclusion Criteria

          -  History or evidence of central nervous system bleeding as defined by stroke or
             intraocular bleed (including embolic stroke) not associated with any antitumor surgery
             within 6 months before enrolment

          -  Known hypersensitivity to immunoglobulins or to any other component of the IP
             formulation

          -  Active infection requiring intravenous antibiotics that was completed less than 1 week
             of study enrolment (day 1) with the exemption of prophylactic antibiotics for long
             line insertion or biopsy

          -  Known positive test for human immunodeficiency virus (HIV)

          -  Active hepatitis B and C based on the following results:

               -  Positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic
                  hepatitis B or recent acute hepatitis B)

               -  Negative HepBsAg and positive for hepatitis B core antibody: hepatitis B virus
                  DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus
                  DNA suggests occult hepatitis B

               -  Positive hepatitis C virus antibody (HepCAb): hepatitis C virus RNA by PCR is
                  necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C

          -  Unresolved toxicities from prior antitumor therapy, defined as not having resolved to
             CTCAE, version 4.0 grade 1 (with the exception of myelosuppression, eg, neutropenia,
             anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the
             exception of alopecia or toxicities from prior antitumor therapy that are considered
             irreversible (defined as having been present and stable for greater than 2 months)
             which may be allowed if they are not otherwise described in the exclusion criteria AND
             there is agreement to allow by both the investigator and sponsor

          -  Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, or
             investigational agent) within 14 days (Group 2 subjects) or 5 half-lives (whichever is
             longer: for Group 1 subjects) of day 1. Avastin, Pembrolizumab must be stopped 14 days
             prior to day 1

          -  Female with a positive pregnancy test.